Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 1.00 |
| ▸ | FLT1 | P17948 | 4/20 | 0.68 |
| ▸ | FLT4 | P35916 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888459 | 0.86 | KDR (1.00) | KDRFLT1FLT4 | |
| SCHEMBL3888686 | 0.84 | KDR (1.00) | KDRFLT1FLT4 | |
| SCHEMBL7256634 | 0.82 | KDR (0.84) | KDRFLT1FLT4 | |
| SCHEMBL3888462 | 0.81 | KDR (1.00) | KDRFLT1FLT4 | |
| SCHEMBL3886479 | 0.81 | KDR (1.00) | KDRFLT1FLT4 | |
| SCHEMBL3883371 | 0.80 | KDR (1.00) | KDRFLT1FLT4 | |
| SCHEMBL3883426 | 0.79 | KDR (1.00) | KDRFLT1FLT4 | |
| SCHEMBL3890292 | 0.79 | KDR (1.00) | KDRFLT1FLT4 | |
| SCHEMBL3884929 | 0.78 | KDR (1.00) | KDRFLT1FLT4 | |
| SCHEMBL3897200 | 0.77 | KDR (1.00) | KDRFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958340-B2 | such as N-[3-methyl-5-(trifluoromethyl)phenyl]-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine; treating breast cancer; use in combination with estrogen receptor modulators such as tamoxifen and raloxifene | MERCK & CO., INC. (US) | 2005-10-25 | — | — | US | claimed |
| US-20040220201-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-11-04 | — | — | US | claimed |
| WO-2003011836-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | claimed |
| EP-2012878-A2 | COMBINATION THERAPY FOR DISEASES INVOLVING ANGIOGENESIS | Bausch & Lomb Incorporated (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007130842-A2 | COMBINATION THERAPY FOR DISEASES INVOLVING ANGIOGENESIS | BAUSCH & LOMB INCORPORATED (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070258976-A1 | Combination Therapy for Diseases Involving Angiogenesis | BAUSCH & LOMB INCORPORATED | 2007-11-08 | — | — | US | disclosed |
| US-6958340-B2 | such as N-[3-methyl-5-(trifluoromethyl)phenyl]-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine; treating breast cancer; use in combination with estrogen receptor modulators such as tamoxifen and raloxifene | MERCK & CO., INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20040220201-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2003011836-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258976-A1 | Combination Therapy for Diseases Involving Angiogenesis | VEGFA, FLT4, TEK | KDR 5/4885FLT1 4/4885FLT4 2/4885 |
| US-20040220201-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885FLT1 4/4885FLT4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.